A Search Service for Abbreviation / Long Form

â–  Abbreviation / Long Form : PF / preservative-free

[Related PubMed/MEDLINE]
Total Number of Papers: 43
[Entries Per Page]
 per page
Page Control
Page: of
Abbreviation:   PF  (>> Co-occurring Abbreviation)
Long Form:   preservative-free
 Abbreviation Variation
 Long Form Variation
 Pair(Abbreviation/Long Form) Variation
No. Year Title Co-occurring Abbreviation
2019 An in vivo confocal, prospective, masked, 36 months study on glaucoma patients medically treated with preservative-free or preserved monotherapy. IOP
2019 Changes in ocular signs and symptoms in patients switching from bimatoprost-timolol to tafluprost-timolol eye drops: an open-label phase IV study. BAK, FDC, IOP, OAG
2019 Effects of Preservative on the Meibomian Gland in Glaucoma Patients Treated with Prostaglandin Analogues. LAS, MG, OAG, PC, PGA
2019 Meibomian gland dropout rate as a method to assess meibomian gland morphologic changes during use of preservative-containing or preservative-free topical prostaglandin analogues. MG, PC
2019 Sterility and Stability Testing of Preservative-free Albuterol. BAC, CAA
2018 Better tolerance of preservative-free latanoprost compared to preserved glaucoma eye drops: the 12-month real-life FREE study. ---
2018 Preservative-free tafluprost/timolol fixed combination: comparative 24-h efficacy administered morning or evening in open-angle glaucoma patients. IOP, TTFC
2018 Preservatives in glaucomamedication. BAK, OSD
2018 Prospective, Randomized, Single Masked, Parallel Study Exploring the Effects of a Preservative-Free Ophthalmic Solution Containing Hyaluronic Acid 0.4% and Taurine 0.5% on the Ocular Surface of Glaucoma Patients Under Multiple Long-Term Topical Hypotensive Therapy. BUT, CGC, GSS, HA, OSDI, Tau
10  2017 24-Hour Efficacy and Ocular Surface Health with Preservative-Free Tafluprost Alone and in Conjunction with Preservative-Free Dorzolamide/Timolol Fixed Combination in Open-Angle Glaucoma Patients Insufficiently Controlled with Preserved Latanoprost Monotherapy. DTFC, IOP, OSD
11  2017 Effect of preservative-free tafluprost on intraocular pressure, pupil diameter, and anterior segment structures in normal canine eyes. ICA, IOP, PD, PI, UBM
12  2017 Long term safety and tolerability of Tafluprost 0.0015% vs Timolol 0.1% preservative-free in ocular hypertensive and in primary open-angle glaucoma patients: a cross sectional study. GSS, IVCM, OSD, OSDI, POAG
13  2016 Effect of preservative removal from fixed-combination bimatoprost/timolol on intraocular pressure lowering: a potential timolol dose-response phenomenon. BAK, IOP
14  2016 Long-term topical application of preservative-free prostaglandin analogues evokes macrophage infiltration in the ocular adnexa. ---
15  2016 Ocular Tolerability of Preservative-Free Tafluprost and Latanoprost: in vitro and in vivo Comparative Study. HCE-T, MGHS40, PGAs
16  2016 Pharmacokinetics, Efficacy, and Safety of the Preservative-free Fixed Combination of Tafluprost 0.0015% and Timolol 0.5% in Healthy Volunteers: A Phase I Comparison vs. the Corresponding Preservative-free Monotherapies. FDC, IOP
17  2016 Preservative-free bimatoprost 0.03% in patients with primary open-angle glaucoma or ocular hypertension in clinical practice. AEs, IOP
18  2016 Preservative-free bimatoprost 0.03%/timolol 0.5% fixed combination in patients with glaucoma in clinical practice. FC, IOP
19  2016 Preservative-free tafluprost in the treatment of open-angle glaucoma or ocular hypertension in India: a phase III clinical trial. CI, IOP, OAG
20  2016 Twenty-four-hour efficacy of preservative-free tafluprost for open-angle glaucoma patients, assessed by home intraocular pressure (Icare-ONE) and blood-pressure monitoring. BP, GAT, Icare-ONE, IOP, OPP, POAG
21  2015 Corneoscleral limbus in glaucoma patients: in vivo confocal microscopy and immunocytological study. DC, IC, LSCM, LTE, OSDI, POV
22  2015 In Vivo Effects of Preservative-free and Preserved Prostaglandin Analogs: Mouse Ocular Surface Study. BAC
23  2015 Safety and tolerability of the tafluprost/timolol fixed combination for the treatment of glaucoma. FC
24  2014 A 6-month study comparing efficacy, safety, and tolerability of the preservative-free fixed combination of tafluprost 0.0015% and timolol 0.5% versus each of its individual preservative-free components. AEs, CI, FC, IOP, PGA, PS, TIM, TS
25  2014 Bimatoprost 0.03%/timolol 0.5% preservative-free ophthalmic solution versus bimatoprost 0.03%/timolol 0.5% ophthalmic solution (Ganfort) for glaucoma or ocular hypertension: a 12-week randomised controlled trial. IOP
26  2014 Excipients of preservative-free latanoprost induced inflammatory response and cytotoxicity in immortalized human HCE-2 corneal epithelial cells. BAK, IL-6, LDH, MGHS40
27  2014 Preservative-free latanoprost eye drops in patients with primary open-angle glaucoma/ocular hypertension. BAK, IOP, POAG
28  2014 Trans-conjunctival aqueous humor outflow in glaucomatous patients treated with prostaglandin analogues: an in vivo confocal microscopy study. IOP, LSCM, MD, PGA
29  2013 Bimatoprost 0.03% preservative-free ophthalmic solution versus bimatoprost 0.03% ophthalmic solution (Lumigan) for glaucoma or ocular hypertension: a 12-week, randomised, double-masked trial. IOP
30  2013 Conjunctival goblet cells density and preservative-free tafluprost therapy for glaucoma: an in vivo confocal microscopy and impression cytology study. GCD, GCs, IC, LSCM
31  2013 In vivo confocal microscopy of meibomian glands in glaucoma. BUT, LSCM, MAD, MGs, OSDI, PGAs, STI
32  2013 Twenty-four hour efficacy with preservative free tafluprost compared with latanoprost in patients with primary open angle glaucoma or ocular hypertension. IOP, OHT, POAG
33  2012 Corneal epithelial cell viability following exposure to ophthalmic solutions containing preservatives and/or antihypertensive agents. BAK, PBS, PQ
34  2012 In vitro and in vivo comparative toxicological study of a new preservative-free latanoprost formulation. BAK, CIC, HCE, IVCM
35  2012 Randomized clinical trial of the efficacy and safety of preservative-free tafluprost and timolol in patients with open-angle glaucoma or ocular hypertension. IOP
36  2012 The cytotoxic effects of preserved and preservative-free prostaglandin analogs on human corneal and conjunctival epithelium in vitro and the distribution of benzalkonium chloride homologs in ocular surface tissues in vivo. BAC, BACmix, HCE, LDH
37  2011 Toxicological evaluation of preservative-containing and preservative-free topical prostaglandin analogues on a three-dimensional-reconstituted corneal epithelium system. BAC, HCE
38  2010 Comparison of the efficacy and tolerability of preservative-free and preservative-containing formulations of the dorzolamide/timolol fixed combination (COSOPTâ„¢) in patients with elevated intraocular pressure in a randomized clinical trial. IOP, PC
39  2009 Long-term immunogenicity of preservative-free hepatitis B vaccine formulations in adults. GSK, LP, PC
40  2008 Conjunctival and corneal reactions in rabbits following short- and repeated exposure to preservative-free tafluprost, commercially available latanoprost and 0.02% benzalkonium chloride. BAK, CIC, FCM, IVCM, PBS, TNFR1
41  2007 Ocular symptoms and signs with preserved and preservative-free glaucoma medications. ---
42  2002 Formulation effects on ocular absorption of brimonidine in rabbit eyes. BAK
43  1994 Epidural diet regimen. ---